Cargando…

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

BACKGROUND: In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup. CASE PRESENTATION: We describe a case of a 32-year-old man with paroxysmal nocturna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shikdar, Sufana, Borogovac, Azra, Mohamad, Elabdallah, Khawandanah, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530370/ https://www.ncbi.nlm.nih.gov/pubmed/34674707 http://dx.doi.org/10.1186/s12959-021-00330-6

Ejemplares similares

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab
por: Alashkar, Ferras, et al.
Publicado: (2020)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Burns, Ethan, et al.
Publicado: (2019)

Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
por: Lobry, Camille, et al.
Publicado: (2019)

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
por: Stern, Robert M., et al.
Publicado: (2019)

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
por: Quist, S. W., et al.
Publicado: (2023)

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
por: Schwartz, Carolyn E., et al.
Publicado: (2021)

Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria
por: Takahashi, Hiroshi, et al.
Publicado: (2022)

Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry
por: Jang, Jun Ho, et al.
Publicado: (2016)

New Insights in Abdominal Pain in Paroxysmal Nocturnal Hemoglobinuria (PNH): A MRI Study
por: De Cobelli, Francesco, et al.
Publicado: (2015)

Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients
por: Barcellini, Wilma, et al.
Publicado: (2018)

Bilateral Multiple Focal Choroidal Excavations in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Huang, Ping, et al.
Publicado: (2019)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia
por: Shikdar, Sufana, et al.
Publicado: (2022)

Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
por: Schrezenmeier, Hubert, et al.
Publicado: (2020)

Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Füreder, Wolfgang, et al.
Publicado: (2020)

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)

The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
por: Alashkar, Ferras, et al.
Publicado: (2018)

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ
por: Daly, R. Paola, et al.
Publicado: (2021)

Popliteal artery thrombosis as a rare complication of paroxysmal nocturnal hemoglobinuria (PNH): A case report
por: Bhusal, Kiran, et al.
Publicado: (2021)

Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
por: Moriyama, Mitsuru, et al.
Publicado: (2021)

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ(©))
por: Kaiser, Karen, et al.
Publicado: (2020)

Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes
por: Höchsmann, Britta, et al.
Publicado: (2011)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
por: Sharma, Ruby, et al.
Publicado: (2015)

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH)
por: Weisshaar, Kimmo, et al.
Publicado: (2020)

Long Non-Coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients
por: Wang, Honglei, et al.
Publicado: (2021)

Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023)

Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
por: Choi, Chul Won, et al.
Publicado: (2017)

COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria
por: Hines, Adam, et al.
Publicado: (2021)

Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
por: Dingli, David, et al.
Publicado: (2023)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
por: Brodsky, Robert A., et al.
Publicado: (2020)

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
por: Galli, Nicole, et al.
Publicado: (2023)

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study
por: Chatzileontiadou, S., et al.
Publicado: (2023)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

PB2040: LACTATE DEHYDROGENASE IS A PREDICTOR OF THROMBOEMBOLISM, AND THROMBOEMBOLISM IS A PREDICTOR OF DEATH, IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS FROM A KOREAN PNH REGISTRY
por: Jang, Jun Ho, et al.
Publicado: (2023)

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria
por: Patir, Pusem, et al.
Publicado: (2015)

Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria
por: Mon Père, Nathaniel, et al.
Publicado: (2018)

Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria
por: Ram, R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c96ms8l44gmkphmkn6sl9c07af